With needleless systems, the stress and anxiety often associated with injections can be significantly reduced, potentially improving treatment adherence and health outcomes
Karademir, E
Ian Ellis dive into the surprising variability of GLP-1 dosing (retatrutide, tirzepatide), even when the weekly dose remains the same
Structural biology research, including cryo-EM studies of semaglutide bound to the GLP-1 receptor that have been deposited in the Protein Data Bank for docking and structure-activity work
ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
YOUR TRANSFORMATION MATTERS We listen to your goals, customize your treatment plan, and prioritize safety and natural-looking results